Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen's dispute with Italy hits Tysabri

This article was originally published in Scrip

Executive Summary

A dispute with the Italian medicines agency AIFA has dragged on sales of the multiple sclerosis drug Tysabri (natalizumab) in the first half of this year, as revenues have had to be set aside pending the outcome of the argument. AIFA maintains that Biogen Idec, which is responsible for distribution of the product in Italy, has exceeded an agreed reimbursement limit, but the company counters that the agreement had expired.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC018237

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel